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Background: Cystic fibrosis (CF) is characterised by impaired mucociliary clearance (MCC), chronic inflammation and infection, and
progressively deteriorating lung function. Inhaled mannitol (Bronchitol) has been shown to increase MCC and cough clearance and FEV1 in CF
patients, contributing to better lung hygiene and consequently a slower decline in lung function. This study was designed to determine the dose
relationship of mannitol treatment and improvement in FEV1 and FVC as well as safety.
Methods: This was a randomised, open-label, crossover, dose response study. Following a 2-week treatment with mannitol 400 mg b.i.d., 48 CF
patients with a mean (SD) FEV1 % predicted of 64 (13.2), received a further 3 treatments with 40 mg, 120 mg or 240 mg b.i.d. for 2 weeks each,
in random order.
Results: The study demonstrated a dose dependent increase in FEV1 and FVC. The 400 mg dose showed the greatest improvement and the 40 mg
dose had no discernible effect. The mean percent change in FEV1 was −1.57%, 3.61%, 3.87% and 8.75% respectively for the 40 mg, 120 mg,
240 mg and 400 mg treatments. There was a statistically significant change in FEV1 for 400 mg compared to 40 mg (pb0.0001) but the difference
with 120 mg and 240 mg did not reach significance.
The mean% change in FVCwas −0.90, 1.74, 3.07 and 8.14, for the 40 mg, 120 mg, 240 mg and 400 mg treatment arms, with p=0.0001, p=0.0037
and p=0.0304 respectively when compared to 400 mg. The highest tested dose of 400 mg had a similar safety profile to the other doses tested.
The change in FEV1 and FVC by dose in the paediatric age group (b18 years) was similar to the results in the adult population.
Conclusion: Based on these results the 400 mg b.i.d. dose has been further studied in phase III trials.
© 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Mannitol; Mucoactive; Mucus clearance; Lung function; FEV11. Introduction
Lung disease is the most important manifestation in terms of
symptoms and treatment required and is by far the most frequent
cause of death in cystic fibrosis (CF). It is manifested by an
impaired clearance of mucus, chronic inflammation and infection
and airway damage [1]. Over many years the lung function
progressively deteriorates until respiratory failure and a range of
other complications develop. The aims in the treatment of CF are⁎ Corresponding author. Tel.: +61 2 9454 7200; fax: +61 2 9451 3622.
E-mail address: brett.charlton@pharmaxis.com.au (B. Charlton).
1 For the CF202 Study Investigators.
1569-1993/$ - see front matter © 2010 European Cystic Fibrosis Society. Publishe
doi:10.1016/j.jcf.2010.08.020to alleviate symptoms, improve quality of life and to slow the
decline in lung function. This is achieved by improving airway
clearance, by eradicating or suppressing the growth of bacterial
pathogens and attenuating airway inflammation.
A formulation of inhaled dry powder mannitol (Bronchitol) is
believed to meet the criteria for a suitable agent for use in CF [2].
Inhaled mannitol creates a sustained osmotic gradient which is
thought to increase the amount of water in the airway lumen
which encourages the hydration and subsequent restoration of the
periciliary fluid layer [3]. This leads to improved clearance of
mucus by ciliary and cough function [3]. It improves mucus
rheology by hydration and possibly by breaking internal
hydrogen bonds between mucins [4], stimulates the release ofd by Elsevier B.V. All rights reserved.
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increases the secretion and flow of fresh mucus to help remove
unwanted debris and pathogens [6] and by stimulating a
productive cough it acts as an expectorant [6] causing reduction
of the mucus load quickly [7]. Inhaled mannitol has been shown
to increase the clearance of airwaymucus in patientswithCF aged
between 16 and 46 years [8] and an initial short term study of
inhaled mannitol showed increase in FEV1 [2]. This study was
designed to determine the optimum dose of mannitol required to
demonstrate clinical improvement in lung function in patients
with CF. Other study outcomes including safety and tolerability
were also assessed.
2. Methods
2.1. Study patients
Patients with CF were recruited from 12 sites in two
countries (Canada 7 and Argentina 5).
Patients with confirmed diagnosis of CF (sweat test or
genotype), aged 7 years or older, able to perform acceptable-
quality spirometry, with a baseline FEV1 between 40% and 90%
of predicted were eligible to participate in the trial.
Key exclusion criteria included haemoptysis of N60 mL in the
previous 12 months, Burkholderia cepacia or MRSA colonisa-
tion, active asthma, pregnancy, breast feeding, heart attack or
stroke in the last 3 months or the need for home oxygen. Active
asthma has been defined as “current symptoms and signs of
asthma”. Since inhaled mannitol may induce bronchospasm in
susceptible patients, patients with active asthma are at risk of
bronchoconstriction and is one reason patients are tested with a
dose of mannitol (mannitol tolerance test [MTT]) prior to starting
therapy.
The concurrent use of nebulised hypertonic saline and beta
blocker medication was not allowed, and a 2-week washout
period was required for patients using hypertonic saline solution
or any new/changed antibiotics or oral steroids. In order to
ensure observed changes in FEV1 and dose effects were due to
inhaled mannitol alone, the concomitant use of rhDNase and
hypertonic saline was avoided.
The protocol stipulated that antibiotic usewas to bemaintained
throughout the study and that any new or changed antibiotic use
was to be followed by a 2-week washout period before
recommencing a treatment period. The patients were allowed to
use their routine antibiotics as per their usual prophylactic
treatment schedule.
2.2. Study design
This was a phase II, randomised, open-label, dose response
crossover study, to determine the dose of inhaled mannitol
required to generate clinical improvements in FEV1 in patients
with confirmedCF. The studywas conducted at 12 sites. Duration
of the study was 13 weeks, including 4 treatment periods of
2 weeks with a 1-week washout between each treatment period.
At screening, patients were assessed against the exclusion
and inclusion criteria, and eligible participants were assessed forairway hyperresponsiveness (AHR) using a MTT of increasing
doses of mannitol. Prior to MTT the majority of patients were
not pre-medicated with a bronchodilator.
Patients were excluded if their FEV1 fell by ≥15% before a
cumulative dose of 475 mg had been administered and they were
classified as MTT positive. MTT negative patients commenced a
2-week treatment with inhaled mannitol at 400 mg b.i.d.
Prior to inhalation of doses during the treatment period patients
inhaled a short acting beta agonist. Salbutamol 400 μg was
delivered via a spacer 15 min prior to mannitol administration
during the study visits. A salbutamol inhaler was dispensed to all
patients for use at home prior to study medication.
Following a 2-week treatment with 400 mg b.i.d., patients
were given further three treatments with 40 mg, 120 mg or
240 mg b.i.d. for 2 weeks each in random order.
Inhaled mannitol (Bronchitol™, Pharmaxis Ltd., Frenchs
Forest NSW, Australia) was blister packed in 40 mg capsules
and administered via an inhaler device (RS01™, Monodose
Inhaler Model 7, Plastiape, Italy). Capsules were loaded into the
inhaler device, punctured, then mannitol inhaled in a deep
controlled manner followed by a 5 s breath hold. The process
was to be repeated until the required number of capsules had
been inhaled.
Order of assessment and treatment was standardized for each
visit, i.e. 1) vital signs measured; 2) spirometry measured (FEV1,
forced vital capacity [FVC], index of airflow limitation [FEV1/
FVC], average forced expired flow over the middle half of the
FVC [FEF25-75], and peak expiratory flow [PEF]); 3) pre-
medication with bronchodilator; 4) mannitol administration; 5)
spirometry repeated, 6) vital signs measured; 7) physiotherapy
and 8) sputum sample collected.
Repeated spirometry was performed twice at all clinic visits:
1) prior to premedication with salbutamol and 2) after the drug
administration. Physiotherapy was performed after the drug
administration and prior to sputum collection. Sputum was
collected 1 h post treatment dose at the clinic. Although chest
physiotherapy was not standardized across the study, the patients
were to continue with their standard physiotherapy. However, it
was important that patients adhered to the same routine of
bronchodilator, mannitol and physiotherapy treatments on each
study day visit.
Patients who performed exercise or chest physiotherapy for
clearing mucus were requested to exercise or have their last
physiotherapy/exercise treatment no closer than 4 h prior to
their scheduled visit as physiotherapy was attended to at the
clinic.
2.3. Study objectives
The primary objective was to determine the optimum dose of
mannitol required to obtain clinical improvement in lung
function by comparing the change in FEV1 and FVC at different
doses of mannitol during 2 weeks of treatment.
The secondary objectives were to determine: (1) the effect on
other measures of lung function, i.e. mean change in FEV1/
FVC, FEF25–75, and PEF (before and after treatment periods),
(2) the presence of acquired bacteria in sputum, (3) changes in
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symptoms scores, (4) expectorated sputum volume post
treatment and (5) the frequency and type of adverse events.
2.4. Lung function measurements
At all visits, pulmonary function testing was conducted
according to ATS Guidelines [9] by suitably qualified and trained
staff. Sites were supplied with a SpiroCard Diagnostic Spirom-
eter, consisting of Z-7000-0030 SpiroCard PC Card Spirometer
(CE 0086) and laptop computer with Windows 2000/XP Office
Medic SWR with network ready database. Spirometers were
calibrated before each patient visit and the results recorded for
quality assurance.
2.5. Sputum microbiology and weight
Sputum samples were collected at screening and post
treatment dose in the clinic at each study visit. The sputum
was collected after spirometry and physiotherapy as a single
sample over one-hour period. Salivary contamination was to be
avoided. When the patients could not easily produce sputum,
sputum was collected after a postural drainage for up to 30 min.
Sputum samples were weighed at each participating clinic
using their own balance and pre-weighed collection jars. Samples
were analysed by the institutional laboratory for microbiology,
using their standard laboratory procedures. The presence of
pathogens was reported in terms of clinical significance by the
study physician.
2.6. Quality of life (QoL)
Health-related QoL was measured using the Revised Cystic
Fibrosis Questionnaire (CFQ-R) [10] which was administered at
the beginning of the study prior to the first 2-week treatment and
completion of each dosing period.
2.7. Respiratory symptoms
At Visits 2, 3, 5, 7 and 9 patients were asked standardized
questions regarding respiratory symptoms over the past 2 weeks
(e.g. breathlessness, cough, sputum production, congestion,
fatigue, and discomfort) [2]. Responses were also obtained for
sinus and nasal symptoms (such as postnasal drip, sore throat,
sinus headache and pressure, nasal itch, nasal blockage, loss of
smell, and mucus colour and production). A reduction in score
indicated an improvement in symptoms.
2.8. Safety
Adverse event assessment, brief physical assessment, vital
signs and spirometry were performed before and after the MTT,
before and after initial administration of each mannitol treatment
and at each follow-up visit. A brief physical examination included
the following measurements: temperature, oxygen saturation,
pulse rate and chest sounds.2.9. Statistical analyses
Sequential treatment dose differences in the change in FEV1
and FVC values from baseline to post intervention were
estimated.A linearmixed-effectsmodel with orthogonal contrasts
was used to compare mean % differences in FEV1 or FVC
improvements at doses of mannitol 40 mg, 120 mg, and 240 mg
relative to the reference dose of 400 mg mannitol. For each of the
three comparisons the true mean difference was estimated using a
95% confidence interval. For each statistical test, a two-sided p
value below 5% was considered as statistically significant.
Baseline values at the start of the subsequent treatment periods
were compared to the baseline values of the first treatment period
in order to identify possible carry-over effects.
2.10. Determination of sample size
Thirty six patients were required to meet the precision of ±2%
for detecting a difference between doses with a power of 0.80 and
an alpha of 0.05 using a two-sided test.
2.11. Ethics
The relevant Research Ethics Boards (REB) in Canada and
the National Administration of Products, Foods and Medical
Technology (ANMAT) in Argentina approved the protocol,
including any amendments, and the Informed Consent Docu-
ment(s) before the study was initiated at each site. Documen-
tation of this approval was provided to the sponsor or the
sponsor's designee.
3. Results
The study was conducted from November 2005 to June
2008.
3.1. Patient demographics and disposition
Overall 85 patients with mild to moderate CF aged 19.9 years±
12.98 (range between 7 and 68 years), with baseline FEV163%±15
were enrolled in the study and included in the safety populations.
Patients who did not meet eligibility criteria, wereMTT positive or
withdrew from the study prior to the treatment were excluded from
continuing with the study (Fig. 1).
The mean fall in FEV1 following the MTT in the 27 patients
who were positive was 17.6% (±3.8) and the mean dose at which
FEV1 fell by 15% was 215.6 mg (±164 mg). It is of note that 22
out of 27 positive patients were not pre-medicated with
salbutamol prior to MTT. There were no demographic indicators
predictive of a positive MTT.
Fifty patients out of 85 screened patients were randomised to
treatment. However, two patients withdrew from the study prior
to receiving any treatment apart from the MTT. One of the
patients was diagnosed with growth of Pseudomonas aeruginosa
and was hospitalized for treatment. The second patient, although
negative to MTT decided to withdraw from the study.
Period 4:
40 or 120 or 
240mg, n=43 
ITT population n=48
Period 1:
400mg, n=48 
Period 2:
40 or 120 or  
240mg, n=44 
Period 3:
40 or 120 or 
240mg, n=44 
Total patient enrolled n=85 
Excluded from enrolled population n=0
Safety population n=85
Excluded 37: 8 failed eligibility criteria, 
27 MTT positive, 2 withdrew prior to 
treatment 
Fig. 1. Patient disposition.
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between 7 and 17 years of age and 19 adult patients aged ≥
18 years, overall mean age 19±13 years, with baseline FEV1
64%±13 [range between 43%and 89%predicted]) commenced on
the 400 mg treatment arm and were included in the intent to treat
(ITT) population (Table 1). Four patients withdrew after the initial
treatment period due to their own decision; however, none of them
withdrew due to adverse events.
Mean compliance in all treatment arms was similar at 92.08%,
96.09%, 96.06% and 93.95% for the 400 mg, 40 mg, 120 mg and
240 mg doses respectively.
3.2. Lung function
Pre-dose spirometry variables were analysed to measure the
effectiveness of the washout period and no significant differencesTable 1
Patient demographic features and baseline characteristics.
Characteristic ITT population N=48
Mean age (range) years 19 (7–68)
Gender (n [%])
Male 26 (54.2)
Female 22 (45.8)
Age group (n [%])
≤11 years 18 (37.5)
12–17 years 11 (22.9)
≥18 years 19 (39.6)
FEV1 (mean±SD)
% predicted 64.1 (13.2)
L 1.86 (0.645)
BMI (mean±SD) kg/m2 19.6 (4.41)
Race
Caucasian 40 (83.3)
Medication taken during study period
rhDNase treatment (n [%]) 0 (0.0)
Antibiotic for systemic use (n [%]) 32 (66.7)
Corticosteroids for systemic use (n [%]) 4 (8.3)
Drugs for obstructive airway disease(n [%]) 41 (85.4)were detected for the start arm values for any variable confirming
effective washout [Table 2]. However, there was a trend for
slightly higher values to appear at the start of the second treatment
period as compared to baseline, suggesting a slight carry-over
effect from the first treatment arm which was 400 mg. b.i.d.
Subsequent arms were randomised to minimise the impact on
overall evaluation of each dose and the levels returned to baseline.
The effects of different mannitol dosages on lung function
parameters are summarised in Table 3.
There was a statistically significant increase in FEV1 for the
400 mg dose compared with the 40 mg dose (8.75% [150 mL]
vs. −1.57% [−0.034 mL], respectively, pb0.0001) [Table 3].
The 120 mg and 240 mg doses showed some efficacy, however,
the effect was smaller than that of 400 mg although this did not
reach statistical significance (p=0.08 and p=0.11 respectively).
The 120 mg and 240 mg doses did also show a significantly
greater improvement than the 40 mg dose (Table 3).
The mean percent change in FVC for the 400 mg treatment arm
was 8.14% (183 mL), while it was −0.90% (−0.037 mL) for the
40 mg treatment arm, 1.74% (20 mL) for the 120 mg treatment arm
and 3.07% (72 mL) for the 240 mg treatment arm. SignificantTable 2
Pre-dose spirometry (regardless of dose received) — ITT Population (Period
1=400 mg).
Period n Mean SD Min Median Max
FEV1
Period 1 48 1.86 0.656 0.8 1.79 3.6
Period 2 44 1.89 0.694 0.8 1.82 3.8
Period 3 44 1.86 0.730 0.7 1.75 3.6
Period 4 43 1.86 0.673 0.8 1.76 3.7
FVC
Period 1 48 2.56 1.056 0.8 2.30 4.8
Period 2 44 2.59 1.059 1.0 2.28 5.0
Period 3 44 2.57 1.091 1.1 2.23 5.2
Period 4 43 2.55 1.013 1.0 2.24 5.0
Table 3
Comparison of relative (%) and absolute (L) change in lung function measures across treatment groups.
Parameter 40 mg 120 mg 240 mg 400 mg
Relative change in FEV1 (%) from baseline
Mean±SD
FEV1 −1.57±9.03 3.61±10.84 3.87±12.79 8.75±12.42
p value vs. 400 mg pb0.0001 p=0.079 p=0.1138
p value vs. 40 mg a p=0.018 p=0.025 pb0.0001
FVC −0.90±7.90 1.74±9.22 3.07±11.68 8.14±10.90
p value vs. 400 mg pb0.0001 p=0.0037 p=0.0304
p value vs. 40 mg a p=0.157 p=0.069 pb0.0001
FEV1/FVC −0.80±5.62 2.11±6.32 0.73±6.69 0.54±6.04
FEF25–75 0.23±21.33 11.26±24.86 6.92±23.66 11.89±34.73
PEF 0.10±11.16 1.62±12.26 2.94±12.79 6.93±14.67
Absolute change in FEV1 (L) from baseline
Mean±SD
FEV1 − 0.03±0.168 0.038±0.150 0.076±0.209 0.150±0.191
FVC −0.037±0.206 0.020±0.206 0.072±0.273 0.183±0.247
FEV1/FVC −0.721±4.289 1.326±4.643 0.326±4.814 0.170±4.360
FEF25–75 −0.013±0.327 0.094±0.291 0.108±0.305 0.136±0.363
PEF −0.050±0.487 −0.003±0.481 0.079±0.558 0.281±0.594
a Post hoc analysis: p value calculated for each dose level vs. 40 mg for FEV1 and FVC using unpaired t-test.
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400 mg arm (pb0.0001, pb0.01 and pb0.05 respectively
[Table 3]). Additionally the changes with the 120 mg and
240 mg doses were not significantly different to that with the
40 mg dose (Table 3).
When comparing the change in PEF a significant difference
was noted between the 400 mg and 40 mg treatment arms (6.93%
vs. 0.10%, p=0.0337), but not for the 120 mg or 240 mg
treatment arms (p=0.12 and p=0.34, respectively).
In addition to the overall population, results were studied by
age group. In particular, the change in FEV1 by dose in the
paediatric age group (b18 years) was similar to the results in the
adult population (Fig. 2) with a statistically significant increase1.00
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Fig. 2. Effect of different dosage regimens on FEV1 (%), i.e. 40 mg, 120 mg,
240 mg and 400 mg b.i.d. 2-week treatment each in patients with CF across age
groups (mean [SE]).in FEV1 for the 400 mg dose compared with the 40 mg dose
(p=0.013 in 6–17 years old patients and p=0.0016 in patients
18 years and above). Significant differences in FVC were also
noted for the 400 mg dose compared with the 40 mg dose in 6–
17 years and 18+ years age groups (p=0.0038 and p=0.0069,
respectively) as illustrated in Fig. 3.3.3. Sputum microbiology and weight
The most common bacteria grown were P. aeruginosa (both
mucoid and non-mucoid) in 56.3% of patients, Staphylococcus
aureus (29.2%), and ‘Other’, (20.8%). No apparent reduction or
increase in sputummicrobiological growth occurred as a result of
treatment. There was a negative relationship between mannitol1.00
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Fig. 3. Effect of different dosage regimens on FVC (%), i.e. 40 mg, 120 mg,
240 mg and 400 mg b.i.d. 2-week treatment each in patients with CF across age
groups (mean [SE]).
Table 4
Change in sputum weight (g) by treatment.
Treatment Change from pre-treatment
Mean (SD) 95% CI
40 mg −0.18 (2.92) −1.14 to 0.78
120 mg −0.24 (2.52) −1.04 to 0.57
240 mg −0.37 (2.64) −1.20 to 0.47
400 mg −0.86 (4.85) −2.37 to 0.65
Table 5
Adverse events considered possibly, probably or definitely related to the study
medication (ITT population).
Preferred terms 40 mg 120 mg 240 mg 400 mg
(n=44) (n=44) (n=44) (n=50)
n (%) n(%) n(%) n(%)
Bronchospasm 2 (4.5) 1 (2.3) 1 (2.0)
Headache 1 (2.3) 1 (2.3) 1 (2.0)
Cough 2 (4.5) 1 (2.3)
Pharyngolaryngeal pain 2 (4.5) 1 (2.3)
Nasopharyngitis 2 (4.5)
Haemoptysis 1 (2.3) 1 (2.3)
Nasal congestion 2 (4.5)
Rhinorrhoea 2 (4.0)
Nausea 1 (2.3)
Vomiting 1 (2.0)
Chest pain 1 (2.3)
Condition aggravated 1 (2.3)
Pyrexia 1 (2.3)
Laryngitis 1 (2.3)
Lung infection 1 (2.3)
Upper respiratory tract infection 1 (2.0)
Barotrauma 1 (2.0)
Arthralgia 1 (2.0)
Musculoskeletal chest pain 1 (2.3)
Dizziness 1 (2.0)
Dysgeusia 1 (2.3)
Dyspnoea 1 (2.3)
Pharyngeal ulceration 1 (2.0)
Respiratory tract congestion 1 (2.3)
Wheezing 1 (2.3)
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and after 2-week treatment, with larger doses resulting in a greater
decrease in sputum weight. A mean decrease by 0.18 g, 0.24 g,
0.37 g and 0.86 g for 40 mg, 120 mg, 240 mg and 400 mg doses
respectively was seen; however the difference between doses was
not significant (Table 4). The reduction in sputum weight after
2 weeks of treatment may result from a reduction in sputum load
after 2 weeks of increased clearance. It appeared also that the
volume cleared during a single treatment was dose dependent.
3.4. Other study outcomes
The CFQ-R respiratory domain score had the highest change
from pre-treatment with the mean (SD) of 13.95 (40.65) for the
400 mg treatment arm vs. 1.15 (43.15), 2.59 (33.29) and 0.97
(42.51) for the 40 mg, 120 mg and 240 mg arms but this did not
achieve statistical significance.
Participants either reported no change or general improve-
ment in respiratory symptoms such as breathlessness, coughing,
sputum production, affected chest and complications associated
with CF, in all treatment arms. Nasal and sinus symptoms were
reported as improved or worse in an equal number of patients.
Vital signs (blood pressure, heart rate, oxygen saturation, body
temperature and weight) were similar at baseline and through-
out the study and were not different between treatment arms.
Most patients at all dose levels had no abnormal chest sounds on
examination at either the pre- or post treatment measure.
3.5. Adverse events
The safety was assessed for the entire safety population
(n=85). In the safety population, throughout the study 19 (22.4%)
patients had adverse events which were considered related to the
study medication. Of these events the most common were
respiratory, thoracic and mediastinal disorders, which accounted
for 15 (17.5%) patients, followed by infections and infestations in
5 (5.9%) patients. Overall the most common preferred terms were
bronchospasm occurring in 5 (5.9%) patients, and headache,
cough and pharyngolaryngeal pain, each occurring in three
(3.5%) patients. Only two (2.4%) events considered related to the
study medication (diarrhoea and bronchospasm each occurring in
one patient) were reported following the MTT challenge. Only
one (1.2%) patient was withdrawn from the study due to an
adverse event (bacteria sputum identified) and this was on the day
of MTT.
Five (5.9%) patients experienced serious adverse events (one
during the MTT challenge, one on 40 mg and three on 120 mg)and five (5.9%) patients' events were deemed severe (two
patients each accounted for one serious adverse event listed also
as severe). All serious adverse events were either exacerbation
of CF, respiratory tract infection or infected sputum samples
requiring hospitalization. One serious and severe CF pulmonary
exacerbation was considered to be possibly related to the study
medication in the 120 mg treatment arm group.
When only ITT population was considered, the number of
adverse events which were judged related to the study medication
was similar between the four different treatment arms (Table 5).4. Discussion
The present study was designed to determine the optimal
dose of mannitol required to demonstrate improvement in lung
function in patients with CF as measured by FEV1 and FVC.
FEV1 has been conventionally used as a primary outcome in CF
clinical trials because it is objective, with less coefficient of
variation and can be easily measured. In addition its decline
predicts mortality and correlates with survival in CF [11,12]. In
addition changes in FVC and other lung parameters are used to
support this primary measure of lung function.
The trial was of an open-label, crossover design. This approach
was taken to reduce the number of patients required because of the
limited patient pool and also to minimise between patient
variabilities. The results provide clear evidence of a dose response
effect between doses of 40 and 400 mg and do not suggest that the
7A. Teper et al. / Journal of Cystic Fibrosis 10 (2011) 1–8design has either masked an effect or provided misleading dose
information.
The reactivity to MTT was assessed in the absence of
bronchodilator in most patients and this resulted in patients being
excluded from subsequent treatment. However prior to treatment
they did use bronchodilator so in future studies the use of
bronchodilator before the MTT would be a more appropriate way
to screen and result in more patients progressing to treatment.
The mannitol doses were randomised except for the first dose
of 400 mg which was always administered first. This was done
to reduce subsequent drop outs due to dose intolerance and
maximise patient retention and thereby maximise the data from
the limited patient pool available in CF studies. No significant
carry-over effects were found, though some carry-over effect
from the first treatment period cannot be completely excluded.
For the later treatment periods all the FEV1 and FVC values
returned to pre-treatment baseline.
The treatment period of 2 weeks was chosen on the basis of
previous studies with hypertonic saline [13] and rhDNase [14],
and a previous phase II trial of inhaled mannitol [2] and was
sufficient to show a dose response effect between doses of 40 mg
and 400 mg but establishing whether this is the maximum
achievable improvement at 400 mg will require a larger study.
The interpretation of results in this study is therefore based only
on the effect of different doses during a 2-week treatment period.
Although the highest possible dose has not been formally
established, the use of more than 10 mannitol capsules for each
dosemay compromise compliance. The 400 mg dose b.i.d. appears
to be a reasonable balance between acceptability and efficacy. The
mean compliance to treatment in all treatment arms was good
(N92%), though further studies are required to adequately assess
long-term compliance. Most other therapeutics in this disease area
experience similar compliance and several studies indicate a 30%
to 70% therapeutic adherence in CF [15–19].
The present study achieved its primary end point of
demonstrating a dose dependent improvement in lung function
as measured by FEV1 and FVC following a 2-week treatment
with inhaled mannitol in patients with CF. Each of the mannitol
dose arms (40 mg, 120 mg, and 240 mg) was compared against
the 400 mg dose arm. The 400 mg dose was the most effective
achieving a statistically significant increase in both FEV1 and
FVC (8.75% [150 mL] and 8.14% [183 mL], pb0.0001
respectively). These findings are in accordance with a previous
study in which the dose of 420 mg bid for 2 weeks produced a
similar increase in FEV1 [2].
In another phase II study the administration of 400 mg b.i.d.
for 12 weeks resulted in a 7% increase in FEV1 [20].
Current guidelines do not provide a threshold for clinically
meaningful improvement in FEV1 inCF. The Phase 3 randomised
trial with rhDNase [21], one of the most widely used mucolytic
agents in CF [22] reported an improvement in FEV1 at 24 weeks
of 5.80% for once daily and 5.60% for b.i.d. treatment. The
change of 8.75% at week 2 with inhaled mannitol is comparable
and considered to be clinically meaningful.
Short term clinical trials with hypertonic saline and rhDNase
have showed similar improvements in FEV1. After 2 weeks of
administration of ultrasonically nebulised hypertonic saline themean change in FEV1 from baseline was an increase of 15.0%,
values returning to baseline after a 2-week wash out period [13].
Ballman et al. [23] showed an improvement in FEV1 of 7.7%
with hypertonic saline and 9.3% with rhDNase following a 3-
week treatment period.
Although the difference in change in FEV1 was statistically
significant for the 40 and 400 mg doses neither 120 nor 240 mg
was statistically significantly different to the 400 mg dose. There
was nevertheless a clear trend of dose dependency. However the
increase in FVC was significantly greater with 400 mg compared
with all other doses, and the most effective dose was based on the
primary end point of change in both FEV1 and FVC. Thus 400 mg
was determined to be the most efficacious dose.
The demographic characteristics of the study population reflect
those of the anticipated patient population suited to treatment i.e.
mild to moderate CF patients. More than 80% of the patients were
using drugs for obstructive airways disease. Microbiological
findings were also typical of a CF cohort with 56.3% of the
patients demonstrating colonisation with P. aeruginosa. As
rhDNase use is known to increase FEV1, it was avoided in order
to ensure that the treatment effect of eachmannitol dose alone could
be measured.
The results in patients above and below 18 years of age both
demonstrated a dose dependent improvement in lung function
as measured by FEV1 and FVC with the highest efficacy at the
400 mg dose in both children and adults. It thus appears that this
dose is applicable to both age groups.
The improvement in lung function was supported by positive
trends in QoL changes. The respiratory domain score CFQ-R
questionnaire showed a trend toward improvement on inhaled
mannitol, with the highest mean change from pre-treatment of
13.95 for the 400 mg treatment arm, however, this did not
achieve statistical significance due to large variability. A change
of 4 points is considered to be clinically significant [24] and this
improvement was reached for the 400 mg dose. It is likely that a
2-week treatment period is not long enough to document robust
changes in QoL measures. In addition, there was also a trend to
no change or general improvement in respiratory symptoms and
effects of treatment on mucus clearance and cough as reported
by the majority of patients at 400 mg.
No apparent overall change in sputummicrobiological growth
occurred as a result of treatment, showing no evidence of
increased microbial growth from mannitol. However, longer and
larger studies may be needed to confirm this.
The safety profile for inhaled mannitol over 2-week
administration supports consideration of longer term administra-
tion, and no apparent dose related trends inAEs or vital signswere
observed. The maximum dose did not appear to have any notable
safety issues compared to lower doses. No serious adverse events
emerged during the 400 mg treatment period. In a study by
Minasian et al. [20] cough has been reported as a main reason for
withdrawal in 6 patients, half of them having a chest exacerbation
at the time of withdrawal, however in the present study cough did
not appear to be a significant issue. The reason for this difference
is not clear though factors may include the use of different devices
and the different treatment periods (12 weeks vs. 2 weeks in the
current study) as well as the recruitment of rhDNase users.
8 A. Teper et al. / Journal of Cystic Fibrosis 10 (2011) 1–8Overall, in the present study the adverse events seen were
characteristic of a CF population.5. Conclusions
The primary measures of both FEV1 and FVC changes
clearly show a dose dependent treatment effect for inhaled
mannitol and show that a 400 mg dose was the most efficacious
and a 40 mg dose had no discernible effect. The 400 mg dose
appears to be the appropriate dose for longer term studies in CF
patients including children. This dose showed the greatest
improvement in spirometric measures and a similar benign
safety profile to other doses. The 40 mg dose showed no
evidence of efficacy and could as such be considered as a non-
effective control dose in long-term studies.Conflicts of interest
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